Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by D. Gruben
Modelling the Costs and Outcomes Associated With Sequence of Treatment With and Without Tofacitinib for the Treatment of Moderate to Severe Rheumatoid Arthritis in the Us
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Pms47 - Cost-Effectiveness of Tofacitinib Compared With Adalimumab in the Treatment of Moderate to Severe Rheumatoid Arthritis in Iran
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pms41 - Cost-Effectiveness Analysis of Tofacitinib in Combination With Methotrexate in the Treatment of Moderate to Severe Rheumatoid Arthritis in Greece
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Experience With Tofacitinib in the Treatment of Resistant Rheumatoid Arthritis
Modern Rheumatology Journal
Total Knee Arthroplasty Treatment of Rheumatoid Arthritis With Severe Versus Moderate Flexion Contracture
Journal of Orthopaedic Surgery and Research
Surgery
Orthopedics
Sports Medicine
Costs of Treatment in Patients With Moderate to Severe Plaque Psoriasis
Archives of Dermatology
Tofacitinib for the Treatment of Psoriasis and Psoriatic Arthritis
Expert Review of Clinical Immunology
Allergy
Immunology
Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-To-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate
Arthritis and Rheumatology
Rheumatology
Allergy
Immunology
Cost-Effectiveness Analysis of Baricitinib Versus Adalimumab for the Treatment of Moderate-To-Severe Rheumatoid Arthritis in Spain
ClinicoEconomics and Outcomes Research
Health Policy
Economics
Econometrics
Finance
Reply To: “Tofacitinib for the Treatment of Severe Alopecia Areata and Variants”
Journal of the American Academy of Dermatology
Dermatology
